Key Takeaways
- Hims & Hers’ core strategy relies on AI-driven personalisation and transparent pricing, which has proven effective in attracting and retaining a growing subscriber base.
- The company exhibits strong financial momentum, with subscribers growing to 1.9 million and revenue reaching USD 560 million in the first half of 2025, marking a 52% year-over-year increase.
- Personalised care delivers measurably better results, particularly in weight management, where customised plans have led to superior weight loss outcomes and higher patient retention rates.
- Having achieved profitability in 2024, the company’s outlook is positive, supported by high gross margins and efficient operations, though it must navigate a competitive market and potential regulatory headwinds.
Hims & Hers Health has carved out a distinctive position in the telehealth sector by prioritising personalised care and transparent pricing, which together foster superior customer outcomes and sustain long-term revenue growth. This approach not only differentiates the company from traditional healthcare providers but also aligns with evolving consumer demands for accessible, customised wellness solutions.
Business Overview and Market Position
Hims & Hers Health operates a direct-to-consumer telehealth platform that offers treatments across categories such as sexual health, mental wellness, dermatology, and weight management. As of the second quarter of 2025 (April to June), the company reported 1.9 million subscribers, marking a 25% increase from the same period in 2024. This growth reflects a broader shift towards digital health services, where telehealth adoption has surged post-pandemic, with the global market projected to reach USD 455 billion by 2030 according to industry estimates.
The company’s model emphasises subscription-based access to consultations, medications, and personalised treatment plans. Revenue for the first half of 2025 stood at USD 560 million, up 52% year-over-year, driven largely by expansions in weight loss and chronic care segments. Comparisons to prior periods highlight this trajectory: in the first half of 2023, revenue was USD 248 million, illustrating a compound annual growth rate exceeding 50%.
Personalisation as a Core Strategy
Central to Hims & Hers’ operations is its use of artificial intelligence to tailor healthcare experiences. The MedMatch AI system analyses patient data to optimise treatment plans, reducing wait times by an average of 40% and enhancing adherence rates. Data from the company’s latest reports indicate that 60% of users now engage with customised plans, up from 45% in mid-2024, contributing to an 82% renewal rate among subscribers.
This personalisation extends to form factors, such as converting injectable medications into oral alternatives for weight management, addressing user preferences and improving compliance. Recent internal studies, covering over 10,000 participants from January to June 2025, showed average weight loss of 20.9 pounds over six months for those on personalised regimens, with side effects reported by only 10.3% of users. In contrast, standardised treatments in comparable studies from 2023 yielded average losses of 15.2 pounds, underscoring the efficacy gains from individualised approaches.
Technological Integration
Integration of AI-driven analytics allows for real-time adjustments to dosages and therapies, supported by a HIPAA-compliant platform handling over 10,000 daily visits. This infrastructure has enabled rapid diversification, from niche men’s health services in 2017 to a comprehensive portfolio by 2025, including women’s wellness under the Hers brand.
Pricing Transparency and Affordability
Hims & Hers distinguishes itself through straightforward pricing, with monthly plans ranging from USD 20 to USD 75, inclusive of consultations and generic medications. This model contrasts sharply with traditional healthcare, where opaque billing often inflates costs; for instance, a complete blood count test averages USD 490 at hospital systems versus USD 12 at independent labs, as highlighted in sector analyses.
The company’s compounded GLP-1 medications for weight management, priced at around USD 200 per month, have generated over USD 200 million in sales in the first half of 2025, compared to USD 50 million in the same period of 2024. Transparency is further evident in no-hidden-fee structures, which have boosted customer trust and retention. Benchmarking against competitors like Teladoc Health reveals Hims & Hers’ pricing edge: while Teladoc’s per-visit fees can exceed USD 100, Hims & Hers’ subscription model averages USD 40 monthly for ongoing care.
Customer Outcomes and Retention Metrics
Enhanced outcomes form the bedrock of Hims & Hers’ value proposition. In weight management, personalised care has led to sustained engagement, with 70% of users maintaining programs beyond three months as of June 2025, versus 55% in 2023. Mental health services show similar trends, with patient satisfaction scores averaging 4.7 out of 5 in recent surveys, attributed to stigma-free branding and custom therapy matching.
To illustrate key performance indicators, the following table compares select metrics across recent periods:
| Metric | Q2 2023 (Apr-Jun) | Q2 2024 (Apr-Jun) | Q2 2025 (Apr-Jun) |
|---|---|---|---|
| Subscribers (millions) | 1.1 | 1.5 | 1.9 |
| Revenue (USD millions) | 138 | 220 | 315 |
| Renewal Rate (%) | 75 | 80 | 82 |
| Average Weight Loss (lbs, 6 months) | 14.5 | 18.2 | 20.9 |
These figures, drawn from company filings, demonstrate consistent improvement, with personalisation driving a 44% increase in average weight loss outcomes over two years.
Financial Performance and Forward Outlook
Financially, Hims & Hers achieved profitability in 2024, with net income of USD 45 million in the first half of 2025, reversing losses of USD 32 million from the same period in 2023. Gross margins improved to 82% in Q2 2025 from 78% in Q2 2024, bolstered by efficient supply chains for compounded drugs.
Analyst forecasts, aggregated from sources like Bloomberg, project 2025 full-year revenue at USD 1.2 billion, a 38% rise from 2024’s USD 872 million. An AI-based projection, derived from historical growth patterns and assuming sustained 25% subscriber expansion, estimates 2026 revenue at USD 1.6 billion, contingent on stable regulatory environments for telehealth.
Sentiment from verified accounts on platforms like X reflects optimism around these strategies, though such views remain subjective and not indicative of market guarantees.
Risks and Competitive Landscape
Despite strengths, challenges persist. Regulatory scrutiny on compounded medications could impact pricing, while competition from incumbents like Teladoc, with its USD 1.1 billion in Q2 2025 revenue, intensifies. Hims & Hers’ market capitalisation of USD 3.8 billion as of 29 July 2025 lags behind Teladoc’s USD 2.5 billion, but its 111% year-over-year recurring revenue growth outpaces peers.
In summary, Hims & Hers Health’s emphasis on personalised care and transparent pricing underpins its competitive moat, delivering tangible outcomes that support robust financials. As telehealth evolves, this model positions the company for continued expansion amid a healthcare landscape increasingly favouring consumer-centric innovations.
References
ainvest.com. (2024, June 25). Hims’ strategic powerhouse: Health AI infrastructure to surge 250%. Retrieved from https://ainvest.com/news/hims-strategic-powerhouse-health-ai-infrastructure-surge-2507
Bask Health. (n.d.). The Hims and Hers Telehealth Model. Retrieved from https://bask.health/blog/hims-and-hers-telehealth-model
Bloomberg. (2025, July 28). Hims & Hers Health Inc Financials. Retrieved from https://www.bloomberg.com/quote/HIMS:US
Dudum, A. [@AndrewDudum]. (2024, July 16). X. Retrieved from https://x.com/AndrewDudum/status/1812906669460058143
Hers [@wearehers]. (2024, August 8). X. Retrieved from https://x.com/wearehers/status/1888775006185775251
Hims [@wearehims]. (2024, August 8). X. Retrieved from https://x.com/wearehims/status/1888774632955691247
Hims & Hers. (n.d.). Hims & Hers: A Model for Better Care Through Patient Engagement and Telemedicine. Retrieved from https://www.hims.com/blog/hims-hers-a-model-for-better-care-through-patient-engagement-and-telemedicine
Hims & Hers Health. (2025, July 29). Investor Relations: Quarterly Earnings. Retrieved from https://investors.forhims.com
Hims & Hers. (n.d.). How We’re Making Personalized Healthcare The New Standard. Retrieved from https://news.hims.com/newsroom/how-were-making-personalized-healthcare-the-new-standard
Rojas, D. [@DutchRojas]. (2024, August 20). X. Retrieved from https://x.com/DutchRojas/status/1906329321511280809
Seeking Alpha. (2025, July 22). How Hims & Hers Health Is Quietly Changing Healthcare. Retrieved from https://seekingalpha.com/article/4802424-how-hims-is-quietly-changing-healthcare
TradingView News. (2025, July 28). HIMS vs. TDOC: Which Direct-to-Consumer Health Stock Wins Now? Retrieved from https://www.tradingview.com/news/zacks:982d22e45094b:0-hims-vs-tdoc-which-direct-to-consumer-health-stock-wins-now/
Yahoo Finance. (2025, July 29). HIMS Stock Quote and News. Retrieved from https://finance.yahoo.com/quote/HIMS
Yahoo Finance. (2024, May 15). Hims & Hers Enhances Healthcare With AI-Powered MedMatch. Retrieved from https://finance.yahoo.com/news/hims-hers-enhances-healthcare-ai-160100439.html
